Skip to main content
. Author manuscript; available in PMC: 2021 Aug 27.
Published in final edited form as: Anticancer Drugs. 2012 Feb;23(2):161–172. doi: 10.1097/CAD.0b013e32834dc279

Figure 5: Pharmacological targeting of VEGFR2/EGFR with vandetanib resulted in downregulation of the target receptors at the protein level, while mRNA remained unaffected.

Figure 5:

A–L: Protein expression of both VEGFR2 and EGFR was significantly reduced after treatment in LLC (A–F) and B16.F10 (G–L), as visualized by immunohistochemical staining of consecutive sections for VEGFR2, EGFR and CD31, magnification 100x. Interstitial dermal cells and some vessels in the skin surrounding the tumor strongly stained for EGFR, representing a good internal positive control (not shown). M+N: mRNA levels of VEGFR2 and EGFR in microdissected tumor vasculature from LLC (M) and B16.F10 (N) tumors. Values represent mean of duplicate qRT-PCR analysis + SD of 6 (LLC) or 5 (B16) animals per group. *p<0.05.